The Food and Drug Administration has approved therapeutic options for the treatment of advanced BRAFV600E-mutated thyroid carcinomas, NTRK fusions, RET-mutated medullary thyroid carcinoma, and RET-fusion papillary thyroid cancer [29]. Here, RET is linked to thyroid gland papillary carcinoma.